Related Experiment Videos
Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral
Insights
Vasodilator therapy improved cardiac function in children with heart failure. While initial benefits were clear, long-term effectiveness varied, with some children experiencing recurrent symptoms.
Area of Science:
- Pediatric Cardiology
- Pharmacology
Background:
- Severe left ventricular dysfunction and mitral regurgitation pose significant challenges in pediatric patients.
- Effective therapeutic strategies for pediatric heart failure are crucial.
Purpose of the Study:
- To evaluate the acute and chronic effects of vasodilator therapy in children.
- To assess the impact of vasodilators on cardiac function and clinical status.
Main Methods:
- A cohort of 13 children (0.2 to 14.5 years) with severe left ventricular dysfunction or mitral regurgitation received vasodilator therapy.
- Acute effects of nitroprusside and hydralazine on cardiac index and stroke index were measured.
- Chronic oral vasodilator therapy was administered to 10 children, with follow-up for clinical improvement and symptom recurrence.
Main Results:
- Acute administration of nitroprusside and hydralazine significantly increased cardiac index and stroke index.
- All children showed early clinical improvement with diminished heart failure symptoms; five became asymptomatic.
- Significant improvements in growth velocity, respiratory rate, heart size, and gallop rhythm incidence were observed after 1 month.
- However, the duration of benefit varied; only four children maintained improvement for over 6 months, with others experiencing recurrence within 1-4 months.
Conclusions:
- Vasodilator therapy demonstrates acute efficacy in improving hemodynamic parameters in pediatric heart failure.
- While initial clinical responses are promising, long-term sustained benefit is variable.
- Further research is needed to optimize chronic vasodilator management strategies in children.
Abstract:
To determine the acute and chronic effects of vasodilator therapy in children, vasodilator therapy was evaluated in 13 children (aged 0.2 to 14.5 years) with severe left ventricular dysfunction or mitral regurgitation. In seven children, nitroprusside increased cardiac index by an average of 33% (P less than .01) and increased stroke index by 29% (P less than .01). In eight children, hydralazine caused a 31% increase in cardiac index (P less than .01) and a 27% increase in stroke index (P less than .02). Ten children received chronic oral vasodilator therapy and were followed for 5.7 +/- 1.4 (SEM) months. Early clinical improvement was observed in every child. Symptoms of heart failure diminished in all, and five children became entirely asymptomatic. A significant (P less than .05) improvement was noted in growth velocity, respiratory rate, heart size, and incidence of gallop rhythm after 1 month of therapy. The duration of the beneficial response to vasodilator therapy varied considerably, however, and significant improvement for the group was not found after 1 month. Four children had sustained clinical improvement for 6 months or longer, but the others experienced recurrent heart failure within 1 to 4 months.